Clinical trial
Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving…
NCT00063570 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00063570 |
|---|---|
| Title | Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy |
| Official title | Phase II Trial of Alimta (Pemetrexed) and Gemzar (Gemcitabine) in Metastatic Breast Cancer Patients Who Have Received Prior Taxane Therapy |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Pemetrexed, Gemcitabine |
| Enrollment | 73 |
| Start date | Jul 1, 2003 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Jul 1, 2003 |
| Last update posted | May 29, 2009 |
| Countries | Puerto Rico, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: